Prescribing information



SANDOSTATIN® LAR® is indicated for the treatment of:

  • Patients with symptoms associated with functional gastro-entero-pancreatic endocrine tumours (e.g. carcinoid tumours with features of the carcinoid syndrome) or patients with advanced neuroendocrine tumours of the midgut or of unknown primary origin where non-midgut sites of origin have been excluded.1
  • Patients with acromegaly in whom surgery is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective.1



  1. SANDOSTATIN® LAR® Summary of Product Characteristics. December 2020.
Rate this content: 
No votes yet
UK | May 2021 | 104730

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at